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Summary: We describe a simple DNA-based method to assign the two common arproteinase inhibitor (ar
antitrypsin) deficiency alleles in the Pi-system (Pi*Z and Pi*S). Two sets of mutated primers are used in the
polymerase chain reaction (PCR), followed by a restriction enzyme digest of the products. The mutated forward
primers create &TaqI site only if the wildtype alleles (mostly M or subtypes) are present and not in the presence
of the Pi*Z or Pi*S alleles. The reverse primers are mutated for an invariant Taq I site which serves as an internal
control site in order to assure the completion of the restriction enzyme digest. The digested PCR products can be
clearly resolved by 2.5% MetaPhore™-agarose gel electrophoresis. This simple PCR probing of the most common
arantiproteinase deficiency alleles can be routinely applied either to samples showing quantitatively decreased ar
antiproteinase values in serum or to blood spots of Guthrie cards used for mass screening purposes. In addition,
this method may provide the opportunity for a simple, rapid, and reliable prenatal diagnosis of arantiproteinase
deficiency in special cases.
Introduction
aj-Antiproteinase (arantitrypsin) is a MT 52000 glyco-
protein mainly synthesized in hepatocytes and alveolar
macrophages. It is an important protease inhibitor and
its major physiological substrate is elastase, particularly
in the lower respiratory tract (1). The arantiproteinase
gene, spanning 12 200 bases, is located on chromosome
14q31—32 (2). It is comprised of six introns and of three
non-coding exons at the 5f-site followed by four coding
exons (3). arAntiproteinase shows considerable genetic
variability. More than 90 different polymorphic alleles
or variants are known (4). The most common allele is
PiMl, which exists in two subtypes, MIA and MIV,
characterized by an alanine or a valine at amino acid
position 213, respectively (5). The majority of the poly-
morphic alleles are associated with normal concentra-
tions of aj-antiproteinase. Some deficiency alleles, how-
ever, are associated with low levels of arantiproteinase
in serum and can either be linked to liver disease and/or
to early onset emphysema. The most common deficiency
alleles are Pi*S and Pi*Z, which exhibit allele fre-
quencies of 0.02-0.04 and 0.01-0.02, respectively, in
European populations. Therefore, approximately 0.2%
of the normal population are homozygous for either the
Pi*S- or the Pi*Z-allele (1). The characterization of the
different arantiproteinase phenotypes is usually
achieved by isoelectric focusing.
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In 1984, Long et al. (6) sequenced the gene for the S vari-
ant at (Xi-antiproteinase and, thus, opened the way to diag-
nosing aj-antiproteinase deficiency alleles at the DNA
level. In the past ten years a large number of different
DNA-based methods to detect deficiency alleles of ar
antiproteinase have been described: restriction fragment
length polymorphism (RFLP) (7), allele specific oligonu-
cleotide hybridisation (ASO) (7), allele specific amplifi-
cation (18), direct sequencing (4), dual-colour detection
by ligase-mediated analysis (9), temperature or denatur-
ing gradient gel electrophoresis (TGGE, DGGE) (10), or
PCR-mediated site-directed mutagenesis (11, 12,13).
In this study, we describe a simple and rapid, non-radio-
active, PCR-based method to detect Z and S mutations
in the aj-antiproteinase gene. The specific improve-
ments in comparison with other hitherto published
DNA-based techniques, in particular with respect to reli-
able quality control procedures, are discussed.
Materials and Methods
DNA preparation
Genomic DNA was prepared from 200 EDTA-treated whole
blood by using the QIAamp Blood Kit from Qiagen No. 29104
(Qiagen, Hilden, Germany) according to the manufacturer's in-
structions. Alternatively, DNA was prepared as described pre-
viously (14).
Polymerase chain reaction (PCR)
For PiZ-specific PCR the following mutated oligonucleotides were
used: AAT-ZF (S'-GGCTGTGCTGACCATCGTC-S1) and AAT-ZR
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(5'-AACTCTTCTTTAATGTCATC£A GG-3'). The A to T and the
C to G substitutions are underlined. The primers were designed
based on the cDNA sequence published by Karachi et al. (15).
For PiS-spccific PCR the following mutated oligonucleolides were
used: AAT-SF (5'-AGGGGAAACTACAGCACCT£G-3') and
AAT-SR (5'-TGGGTACTGTTCTCCTCAT£GAGCATG-3'). Both
G to C substitutions are in italics and. underlined. These primers
were designed based on the genomic DNA sequence published by
Long et al. (6). The PCR reactions were performed separately for
each allele in 0.5 ml reaction tubes. The total reaction volume of
20 μΐ included 1 μΐ genomic DNA, 5 pmol of each primer, 1.25 U
of Taq DNA polymcrase (Boehringer-Mannheim, Germany), 200
μηιοί of dNTPs (Pharmacia, Freiburg, Germany), and 1.5 mmol/1
magnesium chloride. Each sample was subjected to 38 amplifica-
tion cycles of 45 s at 94 °C, 45 s al 53 °C, and 30 s at 72 °C on
Hybaid's thermoreactor OmniGene. Initial denaturation was per-
formed at 94 °C for 5 min and the final extension time was 5 min
at 72 °C.
Restrict ion enzyme digest
The PCR products were digested with Taq I restriction enzyme (10
units/μΐ) purchased from Boehringer-Mannheim (Germany). One
μΐ of Taq I restriction enzyme was added directly to the PCR tube
and incubations were continued for 60 min at 65 °C.
Agarose gel electrophoresis
The entire volume of the digest was loaded onto a submarine gel
and products were resolved in 2.5% MetaPhor™-agarose (Biozym,
Hameln; Germany) at 100 V for two hours. The electrophoresis
buffer was Tris-borate-EDTA (85 mmol/1 Tris, 90 mmol/1 boric
acid, and 2 mmol/1 EDTA) containing ethidium bromide (0.35
mg/1). Bands were visualized by UV fluorescence at 302 nm and
photographed on Polaroid film. The DNA length standard V from
Boehringer-Mannheim (Mannheim, Germany) was used as size
marker. . ,
Results
Detection of the Z-mutation
The Z-mutation is a single-base substitution in exon 5
of the normal Ml (Ala213) allele causing a glutamate to
(A)
G lu
ίΑΑΓ-ZFJGGCTGTGCTG ACCATCGgC
GGCTGTGCTG ACCATCG CG AGAAAGGGAC TGAAGCTGCT GGGGCCATGT TTTTAGAGGC
A
L ys
CATACCCATG TCTATTCCCC CCGAGGTCAA GTTCAACAAA CCCTTTGTCT TGAACAAAAT TCTTAATGAT
ACCAAATCTC CCCTCTTCAT TGGAAAAGTG GTGAATCCCA CCCAGAAATA ACTGCCTGTC GCTCCTCAGC
CCCTCCCCTC CATCCCTGGC CCCCTCCCTG GATGACATTA AAGAAGAGTT
GGAG CTACTGTAAT TTCTTCTCAAfAAT-ZSj
undigested:
RE-digested by Tag I:
250 bp
209 bp > wildtype
227 bp > Z mutation
(B)
Glu
(ΑΑΓ-SFJAGGGGAAACT ACAGCACCTC
AGGGGAAACT ACAGCACCTG
AAAATGAAGA CAGAAGGTGA TTCCCCAACC
TGGGACTGAG GCCCATCAGG ACTGGCCAGA
ACTCTGTATA AACTTGGCTT CCAGAATGAG
GGAGAACAGT ACCCA
CCTCTTGTCA TGGGTfAAT-SR)
GAAAATGAAC TCACCCACGA
T
Val
TGAGGGTGAC CAAGAAGCTG
GGGCTGAGGA GGGTGAACCC
GCCACCACTG AGTTCAGGCA
TATCATCACC AAGTTCCTGG
CCCACACCTC TTAGCCATGT
CACATCCCTG GGTCACTGCT
GCGCCGTCCA TGCTCCATGA
GT ACGAGCTACT
undigested:
RE-digested by Tag I:
285 bp
245 bp > wildtype
264 bp > S mutation
Fig. 1 Nucleotide sequences of the arantiproteinase gene ampli-
fied by PCR and principle of the assay for detection of the Z muta-
tion (A) and of the S mutation (B). The primer sequences are
printed in bold letters and are underlined. Mutated nucleotides are
in italics and doubly underlined. The size of undigested or Taq I
restriction enzyme digested PCR products are indicated.
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lysine substitution at amino acid position 342. The
primer pairs, designed to amplify the sequence contain-
ing the Z mutation (Glu342Lys), produced a 250 base
pair produced from part of exon 5 of the cti-antiprotein-
ase gene. The amplified sequence, including the site of
the mutation and the primers, is depicted in figure 1 (A).
The AAT-ZF primer introduces a diagnostic Taq I site
only if the PCR product is derived from normal alleles
(codon 342 GAG) and not in products from alleles bear-
ing the Z mutation (codon 342 AAG). The presence or
absence of this Taq I site makes it possible to distinguish
between normal and Z mutation-bearing alleles after di-
gestion with Taq 1 restriction enzyme followed by
agarose gel electrophoresis. The AAT-ZR primer intro-
duces an invariant Taq I site in all PCR products. This
Taq I site serves as an internal control for completion
of the restriction enzyme digest. Amplicons from pa-
tients with the homozygous PiZZ phenotype showed
a single band of 227 bp (fig. 2, lane 5). Two bands
of 209 base pairs and 227 base pairs were seen in
PCR products from individuals with PiMZ phenotype
(fig. 2, lane 4). Only a single band of 209 base pairs
was seen in normal phenotypes, e.g. PiMM (fig. 2,
lane 3). Partial digestion cannot account for the results
since incomplete digestion would show an additional
b$nd of 250 base pairs.
Detection of the S-mutation
The S-mutation is a single base substitution in exon 3
causing a glutamate to valine substitution at amino acid
position 264. The primers used to amplify the sequence
that includes the S mutation (Glu264Val) yield a 285
base pairs fragment from part of exon 3 and part of
intron 3 of the arantiproteinase gene. The amplified se-
quence, including the site of the mutation and the prim-
ers, is depicted in figure 1 (B). In the same manner as
for the detection of the Z-mutation, the AAT-SF primer
introduces a diagnostic Taq I site only in the PCR pro-
duct from normal alleles (codon 264 GAA) and not in
that from alleles bearing the S-mutation (codon 264
1 2 3 4 5 6 7 8 9 1 0
213-
Fig. 2 Ethidium-bromide-stained 2.5% MetaPhor™-agarose gel
showing the products of amplified normal and mutant alleles of
arantiproteinase. Base pairs are indicated at the left margin.
(1) and (10) DNA length standard V from Boehringer-Mannheim;
(2)-(5) reuslts of the Z-mutant typing: (2) undigested PCR pro-
duct, (3) PiMM, (4) PiMZ, (5) PiZZ,
(6)-(9) results of the S-mutant typing: (6) undigested PCR pro-
duct, (7) PiMS, (8) and (9) PiMM.
GTA). Again the AAT-SR primer introduces an invariant
Taq I site in all PCR products that serves as an internal
control for the completion of the restriction enzyme di-
gest. Two bands of 245 base pairs and 264 base pairs
were seen in products derived from PiMS individuals
(fig. 2, lane 7) whereas a single band of 245 base pairs
was seen in the normal phenotype, e. g. PiMM (fig. 2,
lane 8). Incomplete digestion would show an additional
band of 285 base pairs.
In a preliminary trial to evaluate the assay, we tested
genomic DNA from 10 patients who showed decreased
quantitative arantiproteinase concentrations in serum
(< 1.1 g/1) as assessed by nephelometric measurements
with the Beckman Array system. Among those, 3 pa-
tients were found to be heterozygous for the Pi*Z-allele
and 2 other patients heterozygous for the Pi*S-allele,
respectively. Five patients did not bear either the Pi*Z
or the Pi*S-allele. Examination of the patients' sera by
isoelectric focusing yielded the same unambiguous re-
sults (data not shown). The 5 patients, showing decreased
arantiproteinase concentrations despite the absence of
the Pi*Z- or Pi*S-allele, were characterized as carriers for
common Pi*M alleles in the heterozygous state.
Discussion
Diagnosis of arantiproteinase deficiency has previously
been based on quantitative measurement of the aranti-
proteinase concentration in serum followed by isoelec-
tric focusing. In specialized laboratories isoelectric fo-
cusing is most reliable to assess the wide variety of dis-
ease-associated ai-antiproteinase deficiency alleles. In
the South German population, the combined frequencies
of uncommon proteinase inhibitor phenotypes are ap-
proximately 7.5% (S. Weidinger, personal communica-
tion). Among these, the 5 phenotypes PiMS, PiMZ,
PiSS, PiZZ, and PiSZ, leading to significantly reduced
aj-antiproteinase levels, comprise 85% of the total.
Therefore, for practical purposes, the detection of these
5 phenotypes appears to be sufficient to account for rea-
sonable diagnostic sensitivity.
We used PCR primer mediated mutagenesis to create
convenient restriction enzyme recognition sites since the
restriction enzyme digest is the most critical step in the
characterization of the arantiproteinase-specific PCR
products and incomplete digestion would result in false
positive results. Therefore, in order to ensure that suc-
cessful Taq I restriction enzyme cleavage of PCR pro-
ducts has occured, we incorporated a second invariant
Taq I restriction site as an internal control site for effec-
tive enzyme action. Alternative methods for detection
of the Z and S mutations, such as allele-specific oligo-
nucleotide hybridisation (ASO), allele-specific amplifi-
cation (ASA), direct sequencing, ligase mediated
analysis, temperature gradient gel electrophoresis, and
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denaturing gradient gel electrophoresis are either time
consuming or less reliable. Therefore, the availability
of a simple and well controlled DNA test like this
one is favoured, not only as a routine laboratory tech-
nique but also for prenatal diagnosis or for mass
screening purposes.
Techniques similar to ours to detect the Z and S muta-
tion of the arantiproteinase gene have previously been
proposed by Dry (11) and Tazelaar et al. (12). Our
method, however, is faster because of shorter PCR cycle
times and shorter restriction enzyme cleaving times. In
addition, much more important is the fact that Diy (11)
and Tazelaar et al. (12) used primers that do not incor-
porate control sites for restriction enzyme cleavage. An-
dresen et al. (13) first designed primers that include con-
trol sites for Tag I and Xmn I restriction enzymes for the
detection of PiZ and PiS, respectively. Our technique is
somewhat faster and uses 2.5% MetaPhore™-agarose
instead of 16% polyacrylamide for electrophoretic reso-
lution of PCR products.
The conditions for DNA extraction, PCR, and agarose
gel electrophoresis are designed so that they can be used
in a very similar manner for other routine diagnostic
DNA tests. These include the diagnosis of the most com-
mon genetic defect (Factor V Leiden) underlying acti-
vated protein C resistance in patients with thrombophilia
(16), the apolipoprotein E genotyping (17), and the diag-
nosis of apolipoprotein B-100 mutation Arg3500Gln
(Braun, unpublished). We consider the potential to run
several different diagnostic assays under defined and
similar conditions as an important step to improve the
quality in processing DNA-based tests in clinical chem-
istry. In conclusion, our method for identifying the most
relevant cti-antiproteinase deficiency alleles is simple,
fast and satisfies the quality control features necessary
for application in routine laboratory settings.
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A Principle of Quality Assessment Using a Competitive Polymerase
Chain Reaction Assay for the Detection of Chlamydia trachomatis
in Cervical Specimens
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Institut f r Klinische Chemie I der Medizinischen Hochschule Hannover, Hannover, Germany
Dedicated to Prof. Dr. Dr. J. B ttner on the occasion of his 65th birthday
Summary: The polymerase chain reaction (PCR)-based identification of Chlamydia trachomatis in clinical speci-
mens should include a built-in control to assess the quality of the whole assay from DNA isolation to detection.
For this purpose we established a competitive PCR assay with the following design. A 215 base-pair DNA fragment
from a Chlamydia trachomatis plasmid sequence was amplified in a polymerase chain reaction. An internal control
DNA was coamplified in the same reaction. The differentiation between the amplified C. trachomatis DNA and the
internal control is based on hybridisation against two different probes using Enzymun Test® DNA detection (Boeh-
ringer Mannheim). The internal control capture probe recognizes an additional 20 base-pair DNA sequence in the
competitor DNA construct. Cervical swabs from 65 C. trachomatis positive patients were used. We examined the
influence of different DNA isolation methods on the sensitivity of the assay. Detection of C. trachomatis from
positive cervical swabs was compared using PCR and competitive PCR assays. The advantage of the competitive
assay was a better assessment of reduced sensitivity arising from inhibitory effects or mistakes during the DNA
preparation or amplification.
Introduction
Use of the polymerase chain reaction for identification
of Chlamydia trachomatis in different specimens, like
urine or cervical swabs, has attained a state of the art in
recent years (1—4). In numerous publications, the diag-
nostic tool of PCR has been compared with the "gold
standard", the culture of Chlamydia trachomatis (5—9).
These comparisons showed that PCR has better diagnos-
tic sensitivity and comparable specificity. False-positive
results were generally absent, and could be eliminated
by using suitable assay conditions (10—12). Exclusion
of false-negative results, however, has hitherto been
largely neglected. Negative results, especially in the de-
tection of obligate pathogenic infectious agents like
Chlamydia trachomatis, should be validated with suit-
able control materials. For this purpose, the control ma-
terials are generally bacterial control strains, which are
prepared and used for amplification of the target DNA
in additional reactions. For this external control of the
DNA isolation and amplification plasmids with an inser-
tion in the target DNA region have also been used (13).
Other authors have described control reactions using a
second primer pair for the coamplification of an addi-
tional DNA fragment of human origin (14, 15). But
these materials do not allow a definite control of each
sample from DNA preparation to detection.
For an optimized quality assessment and the avoidance
of false-negative results, a coamplification of a competi-
tor DNA is an effective tool (16-18). We used a plas-
mid DNA with an insertion in a modified part of the
target DNA region of the Chlamydia trachomatis cryptic
plasmid. This region was shown to be most sensitive for
identification of the infectious agent in comparison to
other genomic regions like rRNA genes or the major
outer membrane protein (19, 20). The internal control
DNA was added to all patient samples and coamplified
with the same pair. We compared the competitive PCR
with a regular PCR assay on an automated analyser sys-
tem, using different DNA isolation techniques.
Materials and Methods
Samples
Samples were collected from patients of various gynaecologic
practices between November 1994 and November 1995. Cervical
swabs were collected with a dacron-tipped swab sets (Becton Dick-
inson). The samples were placed in 500 μΐ lysis buffer containing
10 g/1 Triton-X 100 in physiological saline solution in a sterile
reaction tube (Eppendorf, 2 ml), resuspended and stored at 4-8 °C
until needed.
DNA isolation
Four μΐ of a tRNA solution (10 g/1) (Boehringer Mannheim) were
added to 200 μΐ of the specimen in lysis buffer. For the competitive
PCR the tRNA solution contained an additional 2 μg/l of a compet-
itor DNA. The samples were extracted with an equal volume of
phenol/chloroform (1 + 1), then with chloroform, and finally pre-
cipitated with a threefold volume of ethanol. The sedimented DNA
was washed with 500 μΐ ethanol (75 g/1), dried and dissolved in
100 μΐ Η2Ο. DNA was also isolated using commercial kits like
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QIAmp Blood kit including Qiagen Protease, Q1AEX II Gel Ex-
traction kit (Qiagen), High Pure PCR Template Preparation kit in-
cluding Proteinasc K (Boehringer Mannheim), and Dynabeads
DNA DIRECT kit (Dynal). Preparation protocols were performed
according to manufacturers' instructions.
Imp lemen ta t ion of the polymerase chain reaction
PCR was performed as described by Saiki et al. with the following
modifications (21). Ten μΐ of the sample treated as described above
were added to 40 μΐ of the PCR-mix (PCR-mix: see below) in a
0.5 ml Eppendorf tube. The PCR was carried out with the .primer
pair PCL1/PCL3 in a thermocycler (Landgraf, MWG) for 35 cy-
cles. Each cycle consisted of a denaturation step at 94 °C for 60
seconds, annealing at 55 °C for 60 seconds and elongation at 72 °C
for 60 seconds.
The oligonucleotide sequences were:
PCL1: 5'-CTG TAA CAA CAA GTC AGG TTG CGC-31,
(nucleotides 202-225, (22))
PCL3: 5'-GTA CTA GAG GAC TTA CCT CTT CCC-31,
(nucleotides 416-393, (22))
PCR-mix (50 μΐ total volume): 0.2 mmol/1 dNTPs (Boehringer
Mannheim), 1 μιηοΐ/ΐ each of the oligonucleotides (PCL1, PCL3)
HPLC grade (Boehringer Mannheim), 2 μΐ PCR buffer (Boehringer
Mannheim), 2 U Taq polymerase1) (Boehringer Mannheim), ad
40 μΐ Η2Ο.
For the immunochemical detection the DNA was labelled with dig-
oxigenin-ll-2l-deoxyuridine-5l-triphosphate, which was added to
the deoxynucleoside-triphosphate mixture in the ratio 18:1 (dTTP/
Dig-11-dUTP).
Immunochemica l detection of DNA fragments
Fourty μΐ of the PCR-amplified and digoxigenin-labelled sample
were added to 360 μΐ denaturing reagent (50 mmol/1 NaOH) and
pipetted into sample cups of an ES 300 analyser. The reaction pro-
gramme was started as described in the Enzymun Test® DNA De-
tection instructions (Boehringer Mannheim). The following rea-
gents were also necessary: Biotinylated capture probes were added
to different hybridisation solutions (phosphate buffer, pH 6.5) to a
final concentration of 90 μg/l.
Capture probe 51 Biotin-CAC TTT GTC TCG ATG AGA
(C trachomatis): GAC 3'
(nucleotides 374-354, (22))
Capture probe 5' Biotin-GAT GCT GTC AGC ACT CTG
(internal control): AG 31
C. trachomatis-specific DNA and the internal control DNA were
detected by binding of the biotin-labelled nucleic acids to the
streptavidin solid phase (Enzymun Test® Streptavidin Tubes, Boeh-
ringer Mannheim) in two different reactions. A peroxidase-conju-
gated anti-digoxigenin antibody was added to label the digoxi-
genin. The complex was then visualized by addition of the chromo-
gen di-ammonium 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulpho-
nate) (ABTS); the absorption of the resulting green colour was
measured at 422 nm. Positive samples were determined by a cut-
off value (cut-off = 2 X Enefr, but > 0.1).
!) Enzymes:
Taq polymerase: DNA polymerase EC 2.7.7.7 from TTiermus
aquations
EcoRl: restriction endonuclease from E. coli
Hindlll: restriction endonuclease from Haemophilus in-
fluenzae Rd
BamHl: restriction endonuclease from Bacillus amylo-
liquefaciens H
Generation of the internal control DNA
The whole target DNA region was amplified in two different poly-
merase chain reactions under standard conditions (21) with the
primer pairs PIK1E/PIK3B and PIK2H/PIK4B. The procedure was
as described previously (17).
The sequences were:
PIK1E: 5'-TAA GAA TTC ACA TTT CCT ATC AGC TTA ATG
GAA G-3'
(nucleotides 117-141, (22))
PIK2H: 5f-TAA AAG CTT GCA CGT TCT CTC AAG CAG
GAC-3'
(nucleotides 696-676, (22)) <
PIK3B: 5'-TAA GGA TCC AAG TGT GTG TTC TTA TTG
TTC-31
(nucleotides 370-390, (22))
P1K4B: 5'-TAA GGA TCC CTA GAG AGA CAG GAA ATA
CGC ATG-31
(nucleotides 363-340, (22))
The amplified products were gel purified using Sephaglas-Kit
(Pharmacia) and cleaved with EcoRl1) and BarnHI1) (PIK1E/
PIK4B), with Hindlll1) and BamHV) (PIK2H/PIK3B) and ligated
with £c0RI/////taflII-digested vector pUCBM20 (Boehringer Mann-
heim). Competent bacterial strain E. coli C600 was transformed
with the recombinant plasmid DNA (23).
The plasmid DNA of a positive clone was purified in a large scale
plasmid preparation. One μg plasmid DNA was cut with the re-
striction endonuclease BamHl, gel purified and dephosphorylated.
Further a 26 base-pair DNA fragment was ligated with this vector.
For this purpose we used the following oligonucleotides:
PIK: 5'-AAA AGG ATC CGA TGC TGT CAG CAC TCT
GAG GGA TCC AAA A-31
PIKrev: 5'-TTT TGG ATC CCT CAG ACT GCT GAC AGC ATC
GGA TCC TTT T-3'
Two-hundred ng of the oligonucleotides PIK and PIKrev were hy-
bridized in a total volume of 20 μΐ in 1 mmol/1 2-mercaptoethanol,
5 mmol/1 MgCl2, 100 mmol/i NaCl and 10 mmol/1 Tris-HCl, pH
8.0 for one hour at 37 °C. The double stranded oligonucleotide was
digested with Bam HI, extracted with phenol/chloroform, chloro-
form and dialysed against Tris-EDTA buffer using microdialysis
membranes (Millipore). Twenty ng vector DNA were ligated with
1 ng of the digested double stranded oligonucleotide and amplified
in the E. coli strain C600. After purification in a large scale plasmid
preparation the DNA was ready to use for the PCR assay.
Plasmid preparation
Plasmid preparation was performed according to the instructions
of Qiagen Plasmid Maxi Kit (Qiagen). The DNA was further ex-
tracted with phenol/chloroform, then precipitated with ethanol after
RNase treatment of the plasmid DNA. The preparation was
checked on an agarose gel. Agarose gel electrophoresis was per-
formed on 20 g/1 agarose gels in Tris-borate buffer containing 89
mmol/1 Tris-borate, 2 mmol/1 EDTA, 400 μg/l ethidium bromide,
pH 8.0 (23). Electrophoresis was carried out for 45 minutes with
10 V/cm in Tris-borate buffer. The DNA bands were detected with
an UV transilluminator at 312 nm (23). The concentration of the
DNA was determined by measuring the absorbance at 260 nm. An
absorbance of 1.0 corresponds to approximately 50 mg/1 double-
stranded DNA (23).
Results
Cloning the internal control DNA in E. coli
C. trachomatis DNA isolated from cervical specimens
was amplified in two separate PCR reactions using the
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primer pairs PK1E/PIK4B and PIK3B/PIK2H. All
primers contained additional recognition sites for restric-
tion endonucleases. The joining of the two resulting
DNA fragments via the BamHl restriction sites of
PIK3B and PIK4B generated four substitutions in the
original sequence. More bases were exchanged by intro-
ducing three mismatches next to the cloning site of oli-
gonucleotide PIK4B. After ligation with pUC BM20 and
amplification in E. coli a 26 pase-pair DNA fragment
was introduced in the ΒαηίΆΙ cloning site of the recom-
binant plasmid. The purified DNA was used as an in-
ternal control in the competitive assay.
Checking the assay conditions with internal
control DNA
The application of a competitive PCR assay may result
in a decreased amplification rate of the target DNA
fragment. Therefore we determined the minimal quan-
tity of competitor DNA, which can be coamplified in
the PCR assay. Table 1 shows the results of this
investigation. The internal control DNA was diluted
from 10~~8gto 10~~15g per assay. From each dilution
eight amplifications were performed and the products
were detected with internal control capture probe using
Enzymun Test® DNA Detection. One pg internal con-
trol DNA per 50 μΐ total volume in the reaction mix-
ture was the lowest concentration resulting in a con-
stant absorbance at 422 nm, as indicated by the
increasing coefficients of variation at lower quantities
of internal control DNA.
The effect of DNA isolation methods on the
reliability of the assay
We studied the effect of several DNA isolation methods
on the reliability of the detection of internal control and
target DNA. Table 2 shows the results of these compari-
sons. In part (A) the quality of the preparation of 1 pg
competitor plasmid DNA was tested using five different
isolation methods. Four methods used commercial kits.
Only phenol/chloroform extraction and two kits using
protease digestion and spin column purification resulted
in coefficients of variation lower than 10% (n = 8) for
the measured absorbance values. Using these three
methods, a pool of C. trachomatis positive swabs, resus-
pended in lysis buffer, were coprepared with the compet-
itor DNA. In all cases we found coefficients of variation
lower than five percent for the absorbances of amplified
C trachomatis and competitor DNA.
Competitive PCR versus PCR
For reliable identification of Chlamydia trachomatis in
cervical specimens it was necessary to examine the diag-
nostic sensitivity of the described assay conditions.
Sixty-five PCR-positive samples were determined with
the different PCR assays as shown in figure 1. All assays
included a hybridisation step, and a biotinylated probe
was used in the competitive PCR (a) and PCR (b). There
was good discrimination between the cut-off values and
positive results, although the comparison of these meth-
ods (c) shows a tendency to lower absorbances in the
competitive PCR, which is expressed by the regression
equation 2.19 -I- 0.62x. These differences may depend
on the ratio target DNA/competitor DNA, which is
shown in figure 2, where several dilutions of pooled C.
trachomatis DNA isolated from cervical swabs were ex-
amined in a PCR and a competitive PCR assay.
The efficacy of this system in revealing inhibitory sub-
stances was tested using different concentrations of an
inhibitor solution (commercial washing buffer from a
DNA preparation kit) as shown in figure 2. A decrease
of the internal control absorbances revealed an inhibi-
tory effect in each case (see fig. 2b,c).
In conclusion we found a minimal quantity of 1 pg
competitor DNA, which can be coamplified with the
Chlamydia trachomatis DNA isolated from cervical
swabs. Using suitable DNA isolation methods like phe-
nol/chloroform extraction or spin column purification,
the coefficients of variation for values of internal con-
trol DNA were lower than 10%. A tendency to lower
absorbance values after competitive PCR was shown,
but the diagnostic sensitivity for the identification of
Chlamydia trachomatis in cervical swabs was ade-
quate.
Discussion
The use of PCR in routine diagnosis requires extensive
quality control. There are numerous reports on the use
Tab. 1 Determining the minimum quantity of internal control
DNA in the assay.
Internal control DNA was diluted in several steps (10~8g—
10~~15 g/assay) and amplified by PCR using the primer pair PCL1/
PCL3 (see materials and methods). From each dilution eight ampli-
fications were performed; products were hybridized with the in-
ternal control capture probe. Mean values, standard deviations and
coefficients of variation are shown for the measured absorbances
at 422 nm.
Quantity [g]
Mean value (n = 8)
Standard deviation
Coefficient of variation [%]
1(T8
6.51
0.06
1
io-9
6.47
0.07
1
10-io
6.43
0.06
1
io-11
5.85
0.14
2
io-12
5.99
0.12
2
io-13
4.98
0.50
10
io-14
3.24
1.21
37
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Tab. 2 Effect of DNA preparation technique on the reliability of
the PCR assay.
(A) 1 pg internal control DNA was treated according the protocols
of five DNA isolation methods. (B) Samples from a pool of C.
/rac/ioma/w-positive swabs in a lysis buffer were coprepared with
1 pg of the competitor DNA.
Mean values for absorbances at 422 nm after hybridisation with
internal control capture probe (1C), C. trachomatis specific capture
probe (PC), standard deviations (SD) and coefficients of variation
(CV) are listed (n = 8).
χ (n = 8)
B) Positive pool (PC) with 1 pg internal control DNA (1C)
SD CV [%]
A) Negative control with 1 pg internal control DNA (1C)
Dynabeads DNA DIRECT Kit
High Pure PCR Template Preparation Kit
QIAamp Blood Kit
QIAEX II Gel Extraction Kit
Phenol/Chloroform extraction
1C
1C
1C
1C
1C
4.49
5.61
4.75
2.57
4.63
0.86
0.18
0.50 . ,
1.01
0.21
19
3
10
39
5
High Pure PCR Template Preparation Kit
QIAamp Blood Kit
Phenol/Chloroform extraction
PC
1C
PC
1C
PC
1C
4.54
5.58
4.47
5.85
4.44
5.31
0.09
0.14
0.13
0.12
0.07
0.17
2
3
3
2
2
3
of PCR in the diagnosis of Chlamydia trachomatis from
different specimens (1—3, 6, 7) using commercial and
in-house assays. Some authors have considered the re-
duction of false-positive results by using the commercial
Amplicor kit (Roche) with the uracil N-glycosylase sys-
tem for avoidance of contaminations (10—12). Suitable
control mechanisms for detecting false-negative results
were neglected.
The competitive PCR assay is an effective tool for the
assessment of reduced sensitivity. The advantage of this
method is the coamplification of target and competitor
DNA with the same primer pair to allow a definite con-
trol of all reactions, with an option for a semiquantifica-
tion of the PCR products. Both DNA sequences are
identical, except for a small DNA insertion in the in-
ternal control DNA, which is required for separate iden-
tification of the competitor. Because of the modular de-
sign of the sompetitor, a time-saving co-detection of in-
ternal controls from different assay types is possible in
the daily routine.
Inadequate DNA preparations, insufficient amplifica-
tions, or inhibitory effects (17, 24, 25) may be respons-
ible for a reduced sensitivity. Our results suggest the
following assay design for an effective recognition of
false-negative results:
Design of the assay
Each run consists of the patient samples and negative
controls, which are prepared together with the competi-
tor DNA. In the case of negative results for C. tracho-
E
10
1
0.1
10
1
0.1
a
Competitive PCR cutoff
PCR cutoff
Number of C. trachomatis-
positive cervical swabs
Fig. 1 Comparison of PCR and competitive PCR-based detection
of C. trachomatis from cervical swabs.
JHJ 4
2 4 6
A422nm
Competitive PCR
are sorted pairwise in ascending order for the values under (b). Cut
off values are indicated with a dotted line.
Sixty-five C. trachomatis positive samples were analysed using Under (c) a comparison of PCR versus competitive PCR of the 65
/^XVWMWA«·^«.!,,^. TiOT> /^.\ _ J T>/^T^ /t_ \ Ol_ _ 1 1 * ~. ~. . . . - _ _ *
competitive PCR (a) and PCR (b). Shown are absorbances at 422
nm versus the numbers of samples. The values under (a) and (b)
samples is shown (y = 2.19 + 0.62x, r = 0.62).
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a b" 9
1:1 1:10 1:100 1:1 1:10 1:100
C. trachomatis DNA dilutions
1:1 1:10 1:100
Fig. 2 Competitive PCR and inhibitory effects.
DNA isolated from C. trachomatis positive cervical swabs was
pooled, diluted (1 : 10, 1 : 100) and amplified using PCR (a) and
competitive PCR [C. trachomatis DNA (b), internal control DNA
(c)]. Shown are äbsorbances at 422 nm versus the diluted samples.
To demonstrate the advantage of a competitor DNA for quality
assessment, different concentrations of an inhibitor solution (e. g.
washing buffer (High Pure PCR Template Preparation Kit, Boeh-
ringer Mannheim)) were added to the PCR-Mix:
(o) no inhibitor, (V) 1% inhibitor solution per assay, (D) 2.5%
inhibitor solution per assay, ( ) 5% inhibitor solution per assay.
matis the absorbance values for the amplified competitor
DNA should be compared with those of the negative
control competitors. Differences of more than three stan-
dard deviations of an inter-assay precision (or 10 percent
in comparison with the control) will indicate a reduced
sensitivity. In such cases the assay should be repeated
starting with a new DNA preparation. Furthermore we
propose a control measurement for all äbsorbances of
amplified C. trachomatis DNA between A^nm 0.1-
1.0 (see fig. la). .
Using the described assay design it will be possible to
assess the quality of each sample preparation in an as-
say. It may be possible to avoid false-positive results
by using uracil N-glycosylase to diminish the measured
äbsorbances. But the uracil N-glycosylase system pro-
vides insufficient protection, because it is directed only
at amplicon contaminations. Our advice is to obey gene-
ral guidelines for the avoidance of contaminations (e. g.
separation of working areas) (26).
In summary it is possible to reduce false-positive results
by rigorously following the rules for avoiding contami-
nation. False-negative results, which arise from inade-
quacies in any preparation, can be revealed using the
proposed competitive PCR assay.
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Summary: The study was designed to assess the sensitivity of three commercial assays (which differ in methodol-
ogy, standard and antibodies) for osteocalcin, used for detecting changes in osteocalcin secretion induced by
calcitriol (1,25-dihydroxycholecalciferol) in vivo and in vitro. Osteocalcin levels were determined in serum samples
of 10 osteoporotic women after short term calcitriol treatment, and in the culture medium of human osteoblast-like
cells (n = 22) after 48 h calcitriol exposure. All assays displayed similar sensitivity in detecting osteocalcin pro-
duction in vivo after a 1 μg daily dose of calcitriol. A novel IRMA (CIS), claimed to detect intact osteocalcin,
showed higher osteocalcin values than the other assays, and in vitro showed the best sensitivity; it provides an
appropriate index of the osteocalcin synthetic activity of cultured human osteoblasts.
Introduction
Osteocalcin (bone gla protein) is a major bone matrix
non-collagenous protein. It is a γ-carboxyglutamic acid-
containing protein of 49 amino acids, with a relative
molecular mass of MT 5800. It is synthesized by bone
forming cells and, in small amounts, by odontoblasts. Its
synthesis is vitamin K dependent and markedly stim-
ulated by calcitriol (1,25-dihydroxycholecalciferol) (1).
Blood osteocalcin levels reflect new cellular synthesis,
thereby serving as an index of the total body bone for-
mation (2). Nevertheless, some osteocalcin is released
from bone matrix during bone resorption (3). The deter-
mination of circulating osteocalcin is therefore of clin-
ical interest and has become widely used to discriminate
patients affected by different metabolic bone diseases
(4—6). However, in a single clinical entity such as os-
teoporosis, a great variability in serum osteocalcin is ob-
served. This was ascribed either to the heterogeneity of
the disease (7) or to the differences of analytical meth-
ods and preanalytical factors (8). Owing to such vari-
ability, the detennination of osteocalcin levels in a single
osteoporotic patient has limited clinical relevance. The
same might not be true when monitoring specific meta-
bolic bone modifications or treatments where the
changes in osteocalcin levels, independently of the abso-
lute value, might have a clinical relevance. However, the
sensitivity of different assays in detecting changes in
osteocalcin levels following specific metabolic bone
modifications or treatment has not been folly deter-
mined.
Therefore, we designed the following study to assess the
sensitivity of three different commercial assays for se-
rum osteocalcin, used for detecting changes in osteocal-
cin production induced in vivo and in vitro by a physio-
logical stimulus. For this purpose, we performed sequen-
tial measurements of serum osteocalcin in osteoporotic
patients during and after oral administration of calcitriol
for 7 days, and we measured osteocalcin production in
cultures of human osteoblast-like cells after exposure to
calcitriol for 48 h.
Materials and Methods
In vivo
Ten women (mean age 71 ± 9 years) were admitted to the study
after they had given their oral consent according with the pro-
cedures of our Ethical Committee. All women had a low bone
mass characterized by a T-score, which is the number of standard
deviations below the mean value of bone mineral density of young
adult healthy women, > 2 SD as assessed by dual energy X-ray
absorptiometry (QDR 1000, Hologic, Waltham, MA, USA). Thus
the patients were defined osteopenic according to the WHO panel
(9). None of the subjects was affected by any other disease affect-
ing bone metabolism, and none was under treatment with active
bone agents. Their creatinine clearance was ^  50 ml/min. Creati-
nine was measured by the Jqffe method on the Hitachi 747 (Boeh-
ringer, Mannheim, Germany).
Oral daily doses of 0.5 ng or 1 pg of calcitriol (Rocaltrol, Roche,
Basel, Switzerland) were administered for 7 days to two groups of
five women. For three days before starting the administration of
calcitriol the patients consumed a normal calcium (800 mg/d) and
low sodium (100 mmol/d) diet. During the 7 days of treatment the
calcium content of the diet was reduced to 600 mg/d. Fasting blood
samples for osteocalcin determination were obtained immediately
before, and 2, 4, 8 and 30 days from the beginning of treatment.
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In vi tro
Bone cells were established in culture by a modification of the
Gchron Robey & Termine procedure (10) from trabecular bone
samples obtained from waste materials during orthopaedic surgery
for degenerative diseases or traumatic fractures of the femoral neck
requiring osteotomy procedures. None of the patients (60-80 years
old) submitted to surgery had any metabolic or malignant bone dis-
ease.
Briefly, the trabecular bone was cut into small pieces ( 2 X 2 X 2
mm) and washed thoroughly with commercial standardized Joklik's
modified MEM (Eurobio, Les Ulis, France) serum free medium to
remove non adherent marrow cells. The bone pieces were incu-
bated with the same medium containing 0.5 g/1 collagenase (type
IV, Sigma, St. Louis, MO, USA) at 37 °C for 30 minutes with
rotation. The collagenase digestion was stopped by adding Iscove's
modified Dulbecco's medium (Eurobio, Les Ulis, France) contain-
ing foetal bovine serum, volume fraction 0.2 (HyClone, Logan,
UT, USA). The bone pieces (8-10 for each patient) were then
placed in 25 cm2 flasks and cultured in Iscove's modified medium
containing foetal bovine serum, volume fraction 0.2, 105 U/l peni-
cillin, 100 mg/1 streptomycin, 50000 U/l mycostatin and 0.25 mg/1
amphotericin B. Cells began to migrate within 1 week and reached
confluence after 1 month. At this stage, wells were trypsinized and
plated in 24 multiwell plates. Culture medium was changed every
2-3 days. In order to reduce the possibility of phenotype changes,
all the cells were used at the first passage. Cells at confluence
were divided into two groups, matched for donors: one group was
incubated for 48 h with serum-free fresh medium alone, and the
other with serum-free fresh medium supplemented with 10 nmol/1
calcitriol (Hoffmann-La Roche, Basel, Switzerland).
Assays
For osteocalcin quantification three immunoassays were used:
two isotopic and one non-isotopic. One method was a non-
competitive immunoradiometric assay (IRMA), the other two
were based on competitive methodology (RIA and enzyme
immunoassay, El A).
The IRMA is Elsa-osteo-nat (CIS, Gif-sur-Yvette, France) and
utilizes two monoclonal antibodies against human osteocalcin.
Purified human bone protein is used as standard calibrator. The
antibody linked to the solid phase is directed against the 43-49
fragment whereas the antibody against the 5—13 fragment of
the molecule is labelled with 125I; the reported sensitivity is
0.3 μg/L
The RIA is OSTK-PR (CIS, Gif-sur-Yvette, France). The principle
of the assay is based on competition between 125I-labelled osteocal-
cin and osteocalcin contained in standards or samples to be assayed
for a fixed and limited number of antibody binding sites. The sepa-
ration of bound and free fraction is based on the use of a immuno-
precipitating reagent containing polyethylene glycoi, sodium azide,
sheep anti-rabbit immunoglobulins and non-immunized rabbit im-
munoglobulins. The antiserum is obtained from rabbits after bovine
osteocalcin injections. The detection limit of the method is reported
as 0.5 μg/l. The antibody specificity is not detailed.
The EIA is produced by DAKO (Glostrup, Denmark). The Dako
osteocalcin ELISA is a competitive assay in which samples and
biotinylated osteocalcin are incubated simultaneously in anti-
body-coated microwells. Highly purified bovine osteocalcin is
used as a standard; polyclonal antibodies, directed against the
COOH-terminus of the molecule are used. Osteocalcin standard
and patient specimens are premixed with biotinylated osteocalcin
in white microwells precoated with anti-osteocalcin. Following
the first washing stage, peroxidase-conjugated streptavidin is
added to the optically clear microwells. Following a second
washing stage, the substrate (tetramethylbenzidine, in stabilized
H2O2 solution) is added and the reaction is stopped with 2 mol/1
H2S04; absorbances are measured at 450 nm. The method sensi-
tivity is then 0.3 μg/l.
The radioactivity of the standards and samples in the RIA and
IRMA was measured in a γ-counter (MDA 512, Kontron, Milan, It-
aly).
The absorbances of EIA standards and samples were measured by
an automatic EIA-reader (ΕΤΙ system, Sorin, Sal ggia, Italy). In-
ternal controls were established for all measurements. Sera were
obtained after a 4 °C centrifugation of blood collected in plain
tubes (Vacutainer, Becton Dickinson, Rutherford, NJ, USA) stored
in iced water (11).
The centrifugation and the separation were performed within 1
hour of blood withdrawal. Sera were stored at -20 °C and were
thawed only for analysis, performed contemporarily by two opera-
tors. Cell culture media were treated as sera. Sera and culture me-
dia stored more than 1 month at -20 °C were discarded because
intact osteocalcin became degraded with a 70%—80% loss of im-
munoreactivity.
Statistics
All the in vivo data obtained with each assay were plotted indepen-
dently on time on a normal-probability graph and found to lie on
a straight line. The goodness of fit was tested by the Shapiro-Wilk
test, and the distribution was not significantly different from nor-
mal. At each time the mean percentage difference of the median
from the mean was within 15%. Data were analysed by a one factor
ANOVA for repeated measurements and by Duncan's multiple
range test. Data from the in vitro study were analysed by a one
way ANOVA and by Duncan's multiple range test; basal values
versus after treatment values were compared with the Student's "t"
test for paired observation. Statistical analysis was performed with
UNISTAT, statistical package vs. 3, 1994.
Results
In vivo
After a short course of calcitriol administered daily as
the oral dose of 1 μg, all assays showed the same trend:
osteocalcin serum levels increased reaching a significant
(p < 0.05) peak after 8 days from the beginning of the
treatment and returned to baseline levels within 30 days
(fig. 1, top). Elsa-osteo-nat showed a rise in serum os-
teocalcin (150%) that was higher than that shown by the
EIA (138%) and the OSTK-PR (139%), although it was
not statistically significant.
None of the assays revealed any significant rise of osteo-
calcin concentration during and after the oral treatment
with 0.5 μg daily of calcitriol (fig. 1, bottom).
Before and after treatment with both calcitriol doses, the
absolute values of osteocalcin concentrations measured
with Elsa-osteo-nat were significantly higher (p < 0.01)
than those measured with the other two assays.
In vitro
Basal values of osteocalcin measured with Elsa-osteo-
nat, EIA and OSTK-PR in the culture media of human
osteoblast-like cells did not differ and were 0.012
± 0.001, 0.009 ± 0.003 and 0.011 ± 0.002 g/kg of pro-
tein, respectively. After exposure to calcitriol a highly
significant (p < 0.0001) osteocalcin increase was de-
tected by all the three tested assays. Absolute values of
osteocalcin after calcitriol differ significantly (p < 0.01)
depending on the assays used (fig. 2): Elsa-osteo-nat
showed the highest absolute osteocalcin values.
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Discussion
The aim of this study was to test whether different as-
says, based on different antibodies and analytical meth-
ods, have different sensitivities in detecting stimulated
osteocalcin production by osteoblasts. For this purpose
we measured osteocalcin production after stimulation in
two different experimental conditions, one in vivo and
the other one in vitro.
In the in vivo condition, the ability of the assays to de-
tect the stimulated osteocalcin production would depend
not only upon the characteristics of the assays, but also
on the amount of calcitriol administered. As no assay
detected any significant rise after administration of 0.5
μg it can be speculated that this calcitriol dose was sub-
liminal for the stimulation of osteocalcin production. In
contrast, all assays detected a significant rise in osteocal-
cin production after 1 μg calcitriol, this dose being
above the threshold for the effect.
The choice of scale for expression of response to treat-
ment can modify the conclusion as to which assay dis-
plays the best sensitivity. By considering that the abso-
lute and relative differences in osteocalcin production in
vivo after 1 μg calcitriol were not statistically signifi-
cant, it can be concluded that all assays displayed sim-
ilar sensitivity. However, the highest, although not sig-
nificant, absolute and relative differences in osteocalcin
production detected by Elsa-osteo-nat after stimulation
cast doubt on this conclusion and suggest that this latter
assay is the most sensitive. This suggestion is supported
by the in vitro findings. Human osteoblast-like cells in
culture, when derived from human trabecular explants as
in the present study, provide one of the best techniques
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Fig. 1 Osteocalcin concentrations measured with the different as- administered daily at the oral dose of 1 μ% (top) and 0.5 μ£ (bot-
says in sera of osteoporotic women after a short course of calcitriol torn). Values are expressed as mean ± SEM (n = 5 in each group).
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Fig. 2 Osteocalcin concentrations measured in culture medium of
human osteoblast-like cells before (basal) and after exposure to 10
El: basal; H: calcitriol.
currently available for studies on human bone cell bio-
logy (12) and thus represent an optimal challenge for
the assays. In contrast to the rat osteosarcoma cell
lines, which also produce the peptide in absence of
calcitriol (13), osteocalcin production by cells derived
from human surgery is absolutely dependent on the
presence of calcitriol (14, 15). Under these conditions
the assay response is further characterized, and the
performance of the Elsa-osteo-nat shown; like the
other assays, this assay detected minimal osteocalcin
production in the absence of calcitriol, but it detected
the highest absolute and relative significant differences
in osteocalcin values after calcitriol exposure. Given
the absence of significant differences of the basal val-
ues measured with the three assays, the higher poststi-
mulus values obtained with Elsa-osteo-nat suggest that
this assay is more sensitive than the others in detecting
the stimulus.
In vivo, osteocalcin levels measured with Elsa-osteo-nat
in serum, either after stimulation or in the basal state,
were consistently higher than the absolute values mea-
sured by EIA and OSTK-PR. Even though a great vari-
ability in osteocalcin levels was observed in the stan-
dardization studies, so that certain precautions are advis-
able in comparing absolute values measured with dif-
ferent assays (16, 17), the higher values detected by
Elsa-osteo-nat are surprising if one considers that this is
an assay claimed to measure human intact osteocalcin
without cross reactivity with osteocalcin fragments. It is
possible, however, that the homologous configuration of
EIA
(DAKO)
Elsa-osteo-nat
(CIS)
nmol/1 calcitriol for 48 h. Values are expressed as mean ± SEM
(n = 22).
*: p < 0.01 among assays. ##: p < 0.0001 vs basal.
the assay underlies the higher absolute values detected
by Elsa-osteo-nat with respect to the other assays.
Higher osteocalcin values have indeed been found with
several human homologous assays (18). The better sen-
sitivity of the assay addressed to the intact osteocalcin
molecule might also be associated with a better specific-
ity. Indeed, when it was challenged by measuring sera
treated with monoclonal antibody against amino acids
43-49 of human osteocalcin, non-detectable values
were obtained (19).
Possible underestimation of intact osteocalcin concen-
trations due to the absence of EDTA in the collecting
tubes is unlikely. In fact, the assays were performed im-
mediately after the first thawing, where the advantage
of EDTA for osteocalcin preservation was minimal and
not statistically significant (20).
In conclusion, the three tested assays displayed similar
sensitivity in detecting calcitriol-stimulated osteocalcin
production in osteoporotic women with normal glomer-
ular filtration. In vitro, Elsa-osteo-nat showed the best
sensitivity. All three tested assays can be applied to se-
rial osteocalcin determination for monitoring the trend
of diseases and/or the response to therapy. Only one as-
say, Elsa-osteo-nat, properly reflects the osteocalcin pro-
duction by human osteoblasts in culture.
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